This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.
Zimmer Biomet (ZBH) Business Recovery Continues Despite FX Woe
by Zacks Equity Research
Zimmer Biomet (ZBH) is benefiting from increased provider capacity, resulting in backlog pull-through in the recent quarters.
Here's Why You Should Retain Zimmer Biomet (ZBH) for Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) due to innovative new product launches and solid execution.
National Vision (EYE) Gains From Store Openings Amid Cost Woes
by Zacks Equity Research
National Vision (EYE) continues to roll out its remote care capabilities, which provide doctors with additional levels of flexibility and expand exam capacity in many areas.
Here's Why You Should Buy SmileDirectClub (SDC) Stock Now
by Zacks Equity Research
Investors are likely to benefit from the SmileDirectClub (SDC) stock, backed by strategic alliances and targeted long-term growth.
Zimmer Biomet (ZBH) Q2 Earnings Match Estimates, View Raised
by Zacks Equity Research
Barring S.E.T., Zimmer Biomet (ZBH) records strong growth across each of its business segments in the second quarter.
Zimmer (ZBH) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Zimmer (ZBH) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zimmer Biomet (ZBH) Q2 Earnings Meet Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 0% and 2.42%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Abbott Laboratories, Stryker, Zimmer Biomet and Haemonetics
by Zacks Equity Research
Abbott Laboratories, Stryker, Zimmer Biomet and Haemonetics are part of the Zacks Industry Outlook article.
Globus Medical (GMED) Gains on Innovation, Strategic Deal
by Zacks Equity Research
Globus Medical's (GMED) Enabling technology sales improvement is driven by strong performance of its robotic and imaging system.
Is a Surprise Coming for Zimmer Biomet (ZBH) This Earnings Season?
by Zacks Equity Research
Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Here's Why You Should Retain Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Bruker (BRKR) based on the strong performances of the Bruker BioSpin Group.
4 Medical Product Stocks to Buy Amid Recovering Prospects
by Indrajit Bandyopadhyay
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. ABT, SYK, ZBH and HAE are well poised to gain from the favorable factors.
CVS Health (CVS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
We expect brand price inflation, new product launch, higher utilization and new PBM clients to have contributed to second-quarter growth for CVS Health (CVS).
Henry Schein (HSIC) Set to Post Q2 Earnings: What Awaits?
by Zacks Equity Research
Henry Schein's (HSIC) second-quarter 2023 results are likely to be aided by the Dental business and new buyouts.
Envista (NVST) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Envista (NVST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will US Business Strength Aid Acadia's (ACHC) Q2 Earnings?
by Zacks Equity Research
Strength in US operations, stemming from higher patient days and revenue per patient day, is expected to have aided Acadia Healthcare's (ACHC) Q2 performance. Rising expenses are likely to have partially offset the same.
Zimmer Biomet (ZBH) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bio-Rad Laboratories (BIO) to Post Q2 Earnings: What Awaits?
by Zacks Equity Research
Bio-Rad Laboratories' (BIO) second-quarter 2023 results are likely to reflect an impressive performance across its Clinical Diagnostics business.
Will Zimmer Biomet (ZBH) Beat Estimates This Earnings Season?
by Zacks Equity Research
Zimmer Biomet (ZBH) is expected to have witnessed procedure recovery in its legacy business in the second quarter.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
STERIS (STE) Set to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS' (STE) first-quarter fiscal 2024 results are likely to reflect an impressive performance across the Healthcare and AST segments.
ZBH or PODD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ZBH vs. PODD: Which Stock Is the Better Value Option?
GE HealthCare (GEHC) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
GE HealthCare's (GEHC) Imaging revenue growth in Q2 is expected to have been led by Magnetic Resonance as well as its molecular imaging entity.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
IDEXX Laboratories (IDXX) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
IDEXX Laboratories' (IDXX) second-quarter 2023 results are expected to reflect an impressive performance in the CAG segment.